Posted by Michael Wonder on 07 Sep 2018
Monoferric (iron isomaltoside 1000 for injection) receives marketing approval from Health Canada
6 September 2018 - Pharmacosmos is delighted to announce that marketing approval has been granted for Monoferric (global brand name Monofer) in Canada.
Monoferric is approved for the treatment of iron deficiency anaemia in adult patients who have intolerance or unresponsiveness to oral iron therapy.
Monoferric will be available in Canada in November, 2018. In 2015 Pharmacosmos entered into an agreement with Pfizer Canada who have the exclusive commercialisation rights to Monoferric in Canada.
